Biomarkers of immune checkpoint inhibitor therapy reported include PD‐L1, ratio of tissue‐resident memory T cells to depleted CD8+ T cells in the tumor microenvironment, regulatory T cells, 11‐gene signature, high expression of CD274, T‐effector signature, and intertumoral CD8+ T cell density.45 Here, CD8A is linked to neoplasm.